Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
J Osteopath Med. 2022 Aug 11;122(9):469-479. doi: 10.1515/jom-2021-0172. eCollection 2022 Sep 1.
Opioids are commonly utilized for the treatment of chronic pain. However, research regarding the long-term (≥12 months) outcomes of opioid therapy remains sparse.
This study aims to evaluate the effects of long-term opioid therapy on measures of back-specific disability and health-related quality of life in patients with chronic low back pain.
In this retrospective cohort study, patients with chronic low back pain who reported consistent opioid use or abstinence for at least 12 months while enrolled in the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation Pain Research Registry were classified as long-term opioid users or nonusers, respectively. For comparison, intermediate-term and short-term opioid users and nonusers were also identified. Multiple linear regression analysis was performed to compare back-specific disability (Roland-Morris Disability Questionnaire [RMDQ]) and health-related quality of life (29-item Patient-Reported Outcomes Measurement Information System [PROMIS]) between opioid users and nonusers while controlling for pain intensity, depression, age, body mass index (BMI), and eight common comorbid conditions (herniated disc, sciatica, osteoporosis, osteoarthritis, heart disease, hypertension, diabetes, and asthma). Statistically significant findings were assessed for clinical relevance.
There were 96 long-term opioid users and 204 long-term opioid nonusers. After controlling for potential confounders, long-term opioid use was a predictor of worse back-specific disability (adjusted mean difference=2.85, p<0.001), physical function (adjusted mean difference=-2.90, p=0.001), fatigue (adjusted mean difference=4.32, p=0.001), participation in social roles (adjusted mean difference=-4.10, p<0.001), and pain interference (adjusted mean difference=3.88, p<0.001) outcomes. Intermediate-term opioid use was a predictor of worse back-specific disability (adjusted mean difference=2.41, p<0.001), physical function (adjusted mean difference=-2.26, p=0.003), fatigue (adjusted mean difference=3.70, p=0.002), and sleep disturbance outcomes (adjusted mean difference=3.03, p=0.004), whereas short-term opioid use was a predictor of worse back-specific disability (adjusted mean difference=2.42, p<0.001) and physical function outcomes (adjusted mean difference=-1.90, p<0.001).
The findings of this study are largely consistent with existing literature regarding the outcomes of long-term opioid therapy. Taken in conjunction with the well-established risks of opioid medications, these findings draw into question the utility of long-term opioid therapy for chronic low back pain.
阿片类药物常用于治疗慢性疼痛。然而,关于阿片类药物治疗的长期(≥12 个月)结果的研究仍然很少。
本研究旨在评估长期阿片类药物治疗对慢性腰痛患者的背部特定残疾和健康相关生活质量的影响。
在这项回顾性队列研究中,报告至少 12 个月持续使用阿片类药物或戒断阿片类药物的慢性腰痛患者分别被归类为长期阿片类药物使用者或非使用者。为了比较,还确定了中期和短期阿片类药物使用者和非使用者。在控制疼痛强度、抑郁、年龄、体重指数(BMI)和八种常见合并症(椎间盘突出、坐骨神经痛、骨质疏松症、骨关节炎、心脏病、高血压、糖尿病和哮喘)的情况下,采用多元线性回归分析比较阿片类药物使用者和非使用者之间的背部特定残疾(Roland-Morris 残疾问卷 [RMDQ])和健康相关生活质量(29 项患者报告的结果测量信息系统 [PROMIS])。对有统计学意义的发现进行临床相关性评估。
共有 96 名长期阿片类药物使用者和 204 名长期阿片类药物非使用者。在控制潜在混杂因素后,长期阿片类药物使用是背部特定残疾(调整平均差异=2.85,p<0.001)、身体机能(调整平均差异=-2.90,p=0.001)、疲劳(调整平均差异=4.32,p=0.001)、参与社会角色(调整平均差异=-4.10,p<0.001)和疼痛干扰(调整平均差异=3.88,p<0.001)结果较差的预测因素。中期阿片类药物使用是背部特定残疾(调整平均差异=2.41,p<0.001)、身体机能(调整平均差异=-2.26,p=0.003)、疲劳(调整平均差异=3.70,p=0.002)和睡眠障碍结果(调整平均差异=3.03,p=0.004)较差的预测因素,而短期阿片类药物使用是背部特定残疾(调整平均差异=2.42,p<0.001)和身体机能结果(调整平均差异=-1.90,p<0.001)较差的预测因素。
本研究的结果与现有关于长期阿片类药物治疗结果的文献基本一致。考虑到阿片类药物的既定风险,这些发现使人对长期阿片类药物治疗慢性腰痛的实用性产生质疑。